Impact of gemcitabine (Gem)-or capecitabine (Cape)-based chemoradiation (CRT) on health-relatedquality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial [Abstract]

Mukherjee, Somnath, Hurt, Chris Nicholas ORCID: https://orcid.org/0000-0003-1206-8355, Dutton, Peter, Bridgewater, John A., Crosby, Thomas, Mcdonald, Alec, Falk, Stephen, Abrams, Ross A., Maughan, Timothy Stanley and Griffiths, Gareth 2014. Impact of gemcitabine (Gem)-or capecitabine (Cape)-based chemoradiation (CRT) on health-relatedquality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial [Abstract]. Journal of Clinical Oncology 32 (5) , 4126. 10.1200/jco.2014.32.15_suppl.4126

Full text not available from this repository.

Abstract

Background: HRQL in pancreatic CRT trials have not been widely reported. In SCALOP, registered patients (n=114) received Gem and Cape induction chemotherapy (4 cycles) and non-progressing patients (n=74) were randomized to conformal RT (50.4Gy/28 fractions/5.5 weeks) in combination with Gem (300mg/m2 weekly) or Cape (830mg/m2 bd on days of RT). SCALOP demonstrated superior overall survival (15.2 mo vs 13.4 mo, HR 0.39, p=0.012) and lower Grade 3/4 hematological toxicity (18% v 0%, p=0.008) in the Cape-CRT arm (Mukherjee, Lancet Oncol, Apr 2013). The SCALOP trial was funded by Cancer Research UK (CR UK 07/040). Methods: HRQL was assessed with EORTC QLQ-C30 (generic domains) and EORTC PAN26 (pancreas specific) at Week 0 (pre-treatment), Week17 (pre-CRT), Week23 (post-CRT) and follow-up (Weeks 26, 39). The difference in change in function and symptom scores between trial arms from pre-CRT baseline (week 17) to later time-points were analysed using Wilcoxon rank sum tests. Results: HRQL form completion was 93%, 82%, 65%, 68% and 58% respectively across the time-points. Compared to pre-CRT baseline (week 17), at the end of CRT (week 23), patients on Cape-CRT arm experienced significantly better HRQL outcomes in terms of cognitive functioning (p=0.04), fatigue (p=0.05), bloating (p=0.04) and dry mouth (p=0.03). The differences were no longer significant at week 26 or 39 apart from cognitive function scores (p=0.01) and dry mouth (p<0.01), which remained significant at week 39. Conclusions: The better HRQL in the Cape-CRT arm complements the outcome from the main trial and further supports the use of Cape rather than Gem as concomitant chemotherapy with radiation in LAPC. Clinical trial information: NCT01032057.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	American Society of Clinical Oncology
Last Modified:	01 Nov 2022 10:05
URI:	https://orca.cardiff.ac.uk/id/eprint/90213

Actions (repository staff only)

Edit Item